Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes: A dose-timing study

Diabetes Care

Volumn 26, Issue 11, 2003, Pages 3074-3079

  Weyer, Christian ^a   Gottlieb, Alan ^a   Kim, Dennis D ^a   Lutz, Karen ^a   Schwartz, Sherwyn ^b   Gutierrez, Maria ^c   Wang, Yan ^a   Ruggles, James A ^a   Kolterman, Orville G ^a   Maggs, David G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Diabetes and Glandular Disease Clinic   (United States)

^c Clinical Studies Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; PRAMLINTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; NAUSEA; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; AGED; AMYLOID; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 10744224487     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.11.3074     Document Type: Article

References (29)

1. Felig P, Tamborlane W, Sherwin RS, Genel M: Insulin-infusion pump for diabetes. N Engl J Med 301:1004-1005, 1979
2. Bolli GB, Di Marchi RD, Park GD, Pram ming S, Koivisto VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42:1151-1167, 1999
3. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 26 (Suppl. 1):33-50, 2003
4. American Association of Clinical Endocrinologists: The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 up-date. Endocr Pract 8 (Suppl. 1):40-65, 2002
5. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7:1353-1373, 2001
6. Edelman SV, Weyer C: Unresolved challenges with insulin therapy in type 1 and Lype 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 4:175-189, 2002
7. Buse JB, Weyer C, Maggs DG: Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 20:137-144, 2002
8. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG: Amylin concentrations and glucose control. Lancet 339:1179-1180, 1992
9. Unger RH: Glucagon physiology and patho-physiology. N Engl J Med 285:443-449, 1971
10. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA: Abnormal meal carbohydrate disposition in insulin-dependent diabetes: relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest 74:985-991, 1984
11. Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343, 1995
12. Jacobs MA, Keulen ET, Kanc K, Casteleijn S, Scheffer P, Deville W, Heirie R: Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care 20:1279-1286, 1997
13. Nyholm B, Brock B, Orskov L, Schmitz O: Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opin Investig Drugs 10:1641-1652, 2001
14. Fineman M, Koda J, Weyer C, Shen LZ, Strobel SA, Maggs D, Kolterman O: The human amylin analogue pramlintide corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51:636-641, 2002
15. Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41:577-583, 1998
16. Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD: Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 14:123-131, 2002
17. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A: Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39:492-499, 1996
18. Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46:632-636, 1997
19. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O: The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48:935-941, 1999
20. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730, 2002
21. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 4:51-61, 2002
22. Gottlieb A, Velte M, Fineman A, Kolterman OG: Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks (Abstract). Diabetes 49 (Suppl. 2): A109, 2000
23. Hollander PA, Levy P, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: a one year randomized controlled trial. Diabetes Care 26:784-790, 2003
24. Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
25. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M: Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 13:625-629, 1996
26. Heise T, Heinemann L: Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des 7:1303-1325, 2001
27. Kang S, Creagh FM, Peters JR, Brange J, Volund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27, AspB10, AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 14:571-577, 1991
28. Bolli GB: Clinical strategies for controlling peaks and valleys: type 1 diabetes. Int J Clin Pract Suppl 129:65-74, 2002
29. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglycerides excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26:1-8, 2003